Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model
Taihua Yang, Marion Poenisch, Rajendra Khanal, et al.
Journal of Hepatology (2021) Vol. 75, Iss. 6, pp. 1420-1433
Open Access | Times Cited: 124

Showing 1-25 of 124 citing articles:

CRISPR/Cas9 therapeutics: progress and prospects
Tianxiang Li, Yanyan Yang, Hongzhao Qi, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 321
Lipid Nanoparticles Optimized for Targeting and Release of Nucleic Acid
Yaru Jia, Xiu‐Guang Wang, Luwei Li, et al.
Advanced Materials (2023) Vol. 36, Iss. 4
Closed Access | Times Cited: 56
Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma
Marc Wehrli, Samantha Guinn, Filippo Birocchi, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 9, pp. 1859-1877
Closed Access | Times Cited: 30
Chimeric antigen receptor-modified macrophages ameliorate liver fibrosis in preclinical models
Hanren Dai, Cheng Zhu, Qian Huai, et al.
Journal of Hepatology (2024) Vol. 80, Iss. 6, pp. 913-927
Closed Access | Times Cited: 26
Frameworks for transformational breakthroughs in RNA-based medicines
John R. Androsavich
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 6, pp. 421-444
Closed Access | Times Cited: 26
Loss of liver function in chronic liver disease: An identity crisis
Carmen Berasain, María Arechederra, Josepmaría Argemí, et al.
Journal of Hepatology (2022) Vol. 78, Iss. 2, pp. 401-414
Open Access | Times Cited: 56
Recent Advances in Site-Specific Lipid Nanoparticles for mRNA Delivery
Xiao Xu, Tian Xia
ACS Nanoscience Au (2023) Vol. 3, Iss. 3, pp. 192-203
Open Access | Times Cited: 38
mRNA nanodelivery systems: targeting strategies and administration routes
Mujie Yuan, Zeyu Han, Yan Liang, et al.
Biomaterials Research (2023) Vol. 27, Iss. 1
Open Access | Times Cited: 32
Targeting materials and strategies for RNA delivery
Lixin Lin, Kexin Su, Qiang Cheng, et al.
Theranostics (2023) Vol. 13, Iss. 13, pp. 4667-4693
Open Access | Times Cited: 28
Runt-related transcription factor-1 ameliorates bile acid–induced hepatic inflammation in cholestasis through JAK/STAT3 signaling
Liangjun Zhang, Qiong Pan, Lu Zhang, et al.
Hepatology (2023) Vol. 77, Iss. 6, pp. 1866-1881
Open Access | Times Cited: 24
TRIB3–TRIM8 complex drives NAFLD progression by regulating HNF4α stability
Meng‐Chao Xiao, Nan Jiang, Lilin Chen, et al.
Journal of Hepatology (2024) Vol. 80, Iss. 5, pp. 778-791
Closed Access | Times Cited: 16
Delivery Strategy to Enhance the Therapeutic Efficacy of Liver Fibrosis via Nanoparticle Drug Delivery Systems
Jie Liu, Jinhu Liu, Weiwei Mu, et al.
ACS Nano (2024) Vol. 18, Iss. 32, pp. 20861-20885
Closed Access | Times Cited: 14
Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications
Yingying Shi, Miaoyuan Shi, Yì Wáng, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 11
Lipid nanoparticles as the drug carrier for targeted therapy of hepatic disorders
Runxuan Chu, Yi Wang, Jianglong Kong, et al.
Journal of Materials Chemistry B (2024) Vol. 12, Iss. 20, pp. 4759-4784
Closed Access | Times Cited: 9
Research Advances of Lipid Nanoparticles in the Treatment of Colorectal Cancer
Junyi Zhang, Kamran Ali, Jianwei Wang
International Journal of Nanomedicine (2024) Vol. Volume 19, pp. 6693-6715
Open Access | Times Cited: 9
Revolutionizing Dentistry: Preclinical Insights and Future Applications of mRNA Vaccines in Dentistry—A Narrative Review
Luciana Koren, Andro Koren, Robert Likić, et al.
Dentistry Journal (2025) Vol. 13, Iss. 2, pp. 79-79
Open Access | Times Cited: 1
mRNA – A game changer in regenerative medicine, cell-based therapy and reprogramming strategies
Oleksandra Chabanovska, Anne-Marie Galow, Robert David, et al.
Advanced Drug Delivery Reviews (2021) Vol. 179, pp. 114002-114002
Open Access | Times Cited: 52
Recent Advancements in Antifibrotic Therapies for Regression of Liver Fibrosis
Anshika Jangra, Ashish Kothari, Phulen Sarma, et al.
Cells (2022) Vol. 11, Iss. 9, pp. 1500-1500
Open Access | Times Cited: 33
Insights on drug and gene delivery systems in liver fibrosis
Kunj Vyas, Mayur M. Patel
Asian Journal of Pharmaceutical Sciences (2023) Vol. 18, Iss. 2, pp. 100779-100779
Open Access | Times Cited: 20
FXR and NASH: an avenue for tissue-specific regulation
Zakiyah Henry, Vik Meadows, Grace L. Guo
Hepatology Communications (2023) Vol. 7, Iss. 5
Open Access | Times Cited: 18
Hepatocyte dedifferentiation profiling in alcohol-related liver disease identifies CXCR4 as a driver of cell reprogramming
Beatriz Aguilar‐Bravo, Sílvia Ariño, Delia Blaya, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 3, pp. 728-740
Open Access | Times Cited: 17
Navigating the intricate in-vivo journey of lipid nanoparticles tailored for the targeted delivery of RNA therapeutics: a quality-by-design approach
Ehsan Bitaraf Haghighi, Samira Sadat Abolmaali, Ali Dehshahri, et al.
Journal of Nanobiotechnology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 8
mRNA and gene editing: Late breaking therapies in liver diseases
Nerea Zabaleta, Laura Torella, Nicholas D. Weber, et al.
Hepatology (2022) Vol. 76, Iss. 3, pp. 869-887
Open Access | Times Cited: 24
The Role of Nuclear Receptors in the Pathogenesis and Treatment of Non-alcoholic Fatty Liver Disease
Zhenhua Yang, Awang Danzeng, Qiumeng Liu, et al.
International Journal of Biological Sciences (2023) Vol. 20, Iss. 1, pp. 113-126
Open Access | Times Cited: 16
Inhibition of CSF1R and KIT With Pexidartinib Reduces Inflammatory Signaling and Cell Viability in Endometriosis
Timothy N. Dunn, Dominique I. Cope, Suni Tang, et al.
Endocrinology (2024) Vol. 165, Iss. 4
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top